ARCA biopharma, Inc.NASDAQ
Mon, Nov. 14, 4:35 PM
Tue, Aug. 9, 5:07 PM
Wed, May 11, 4:53 PM
- ARCA biopharma (NASDAQ:ABIO): Q1 EPS of -$0.40.
Fri, Mar. 18, 6:22 AM
- ARCA Biopharma (ABIO) FY15 results: Revenues: $0; R&D Expense: $7.1M (+26.8%); SG&A: $4.4M (+7.3%); Net Loss: ($11.5M) (-18.6%); Loss Per Share: ($1.82) (+45.0%); Quick Assets: $38.8M (+151.9%).
- No guidance given.
Thu, Mar. 17, 4:33 PM
- ARCA biopharma (NASDAQ:ABIO): FY15 EPS of -$1.82 vs. -$3.31 in FY14
Nov. 24, 2015, 9:17 AM
Nov. 12, 2015, 5:13 PM
- ARCA biopharma (NASDAQ:ABIO): Q3 EPS of -$0.31.
Sep. 8, 2015, 12:41 PM
Sep. 3, 2015, 4:41 PM
Aug. 11, 2015, 4:40 PM
- ARCA biopharma (NASDAQ:ABIO): Q2 EPS of -$0.10.
Jun. 11, 2015, 9:39 AM
- ARCA biopharma (ABIO +6%) enters into a stock purchase agreement with a group of institutional investors for the sale of 42M units at $0.8805 per unit. Each unit consists of one share of ABIO common stock and one warrant to purchase 0.40 of a share of common stock at $0.8716. Closing date is June 16.
- Net proceeds of ~$34M will fund the clinical development of Fast Track-designated Gencaro (bucindolol), including GENETIC-AF, the ongoing Phase 2b/3 study for the prevention of atrial fibrillation, and working capital.
- The company says that its current cash and cash equivalents, including this placement, will be sufficient to fund operations through 2017.
Apr. 13, 2015, 10:20 AM
- The FDA designates ARCA biopharma's (ABIO +22.6%) lead product candidate, Gencaro (bucindolol HCl), for Fast Track review for the prevention of atrial fibrillation/atrial flutter in a genetically targeted heart failure population (those with reduced left ventricular ejection fraction). In a earlier sub-study of the BEST Phase 3 trial, patients with the combination of beta-1 389 and alpha-2C polymorphisms appeared to respond better to Gencaro.
- The company has identified common genetic variations that it believes will predict an individual patient's response to Gencaro, potentially making it the first genetically-targeted atrial defibrillation prevention treatment. It is currently being evaluated in a Phase 2b/3 study called GENETIC-AF, cosponsored by Medtronic (MDT +0.8%).
- Atrial defibrillation affects over 2.7M Americans, with as many as 500K new cases each year. Globally the number is greater than 33.5M.
- Fast Track status provides for more frequent access to the FDA review team and a rolling review of the New Drug Application (NDA).
Feb. 20, 2015, 7:15 AM
- The World Health Organization (WHO) approves the use of a 15-minute point-of-care test developed by Corgenix Medical (OTCQB:CONX) to detect the presence of the Ebola virus. The company developed the assay with funding assistance of the Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation.
- Procurement and roll-out in Africa will begin in a few weeks pending the completion of administrative procedures with the U.S. FDA.
- Ebola-related tickers: (NYSE:MRK) (NASDAQ:NLNK) (NYSEMKT:IBIO) (NASDAQ:NVAX) (NYSE:GSK) (NYSE:JNJ) (NASDAQ:TKMR) (NYSEMKT:HEB) (NASDAQ:BCRX) (NASDAQ:SRPT) (NASDAQ:CMRX) (NASDAQ:ABIO) (OTCQB:AEMD) (OTCPK:BVNRY) (NASDAQ:INO) (OTCQX:RHHBY)
Jan. 22, 2015, 12:12 PM
- Thinly-traded micro cap NanoViricides (NNVC +20.5%) moves up in early trading on higher volume albeit on modest turnover of 230K shares. Before the open, the company announced that it shipped several anti-Ebola nanoviricide drug candidates to an unnamed "hi-security bio-containment facility" for evaluation.
- The company states that it progressed from design to synthesis of the drug candidates in only four months using its rapid design platform.
- Related tickers: (TKMR +0.2%)(BCRX -2.9%)(HEB -3.2%)(INO -2.3%)(SRPT -0.4%)(CMRX -1.4%)(ABIO -1.6%)
Dec. 15, 2014, 8:02 AM
- The first patient has been dosed in a Phase 1 study assessing the safety, tolerability and pharmacokinetics of BioCryst Pharmaceuticals' (NASDAQ:BCRX) BCX4430 for the treatment of hemorrhagic fever caused by viruses such as Ebola and Marburg. The trial will enroll up to 88 healthy volunteers who will receive a singe injection of BCX4430 in part one of the trial and will receive it over seven days in part two.
- BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families.
- The National Institute of Allergy and Infectious Diseases, National Institutes of Health and the Department of Health and Human Services are funding the work.
- Related tickers: (NASDAQ:ABIO) (NASDAQ:TKMR) (NASDAQ:SRPT) (NYSEMKT:HEB) (NASDAQ:CMRX)
Dec. 11, 2014, 11:21 AM
- Although off its intraday high, thinly-traded nano cap Arca biopharma (ABIO +16.3%) jumps again on an 8x surge in volume in less than two hours of trading. Shares are up 66% from Tuesday's low of $0.70.
- Yesterday, the FDA granted Orphan Drug status to rNAPc2 for the treatment of hemorrhagic fever caused by four families of viruses, including Ebola and Marburg.
- Previously: Arca TF inhibitor an Orphan Drug for hemorrhagic fever (Dec. 10, 2014)